Elicio Therapeutics Announces Upcoming Presentations on Cancer Vaccines
Elicio Therapeutics, Inc. (NASDAQ: ELTX), a leading biotech firm, has revealed important upcoming presentations highlighting their groundbreaking mKRAS-specific amphiphile vaccines. These presentations, scheduled over the next few months, will showcase their latest findings from clinical trials and ongoing research.
First Presentation at AACR Special Conference
The first presentation is set for the American Association for Cancer Research (AACR) Special Conference, running from September 15-18. This event will focus on advancements in pancreatic cancer research. Notably, Dr. Eileen O’Reilly from Memorial Sloan Kettering Cancer Center will present findings from the recent Phase I AMPLIFY-7P trial.
Details of the AACR Presentation
Title: Pancreas Cancer 2024: Translating genomic findings into clinical actionability
Presenter: Dr. Eileen M. O’Reilly
Date and Time: September 15, 5:50 p.m. ET
Second Presentation at RAS-Targeted Drug Development Summit
Next, a second presentation will take place on September 25 at the RAS-Targeted Drug Development Summit. Here, Dr. Pete DeMuth, Chief Scientific Officer at Elicio, will share crucial insights on the clinical translation of Elicio's RAS-targeted amphiphile vaccines, particularly focusing on their mKRAS vaccination strategy.
Details of the RAS Summit Presentation
Title: Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity
Presenter: Dr. Peter C. DeMuth
Date and Time: September 25, 11:45 a.m. ET
Third Presentation at Precision Oncology Institute Symposium
The third presentation will occur on October 1 at the Stuart and Molly Sloan Precision Oncology Institute Symposium. Dr. Christopher Haqq, Elicio’s Executive Vice President and Chief Medical Officer, will discuss the Phase I experience with two specific vaccine candidates: ELI-002 2P and ELI-002 7P.
Details of the Precision Oncology Institute Presentation
Title: Amplifying tumor-specific immunity through lymph node-targeted mKRAS-specific amphiphile vaccine in gastrointestinal tumors
Presenter: Dr. Christopher M. Haqq
Date and Time: October 1, 9:40 a.m. PT
CEO's Thoughts on Recent Patient Data
Robert Connelly, the CEO of Elicio, expressed his excitement over recent data from patients who received the 7-peptide version of ELI-002. He pointed out that the T cell response data was positively linked to lower tumor biomarker levels and reduced risks of progression or death. Connelly stated, "With $43 million raised in funding for 2024, we're hopeful about our forthcoming clinical updates and the upcoming results from the AMPLIFY-201 trial. We expect to share more insights later this year and an early analysis from the AMPLIFY-7P randomized Phase 2 trial early next year."
Understanding Elicio Therapeutics
Elicio Therapeutics aims to tackle some of the most aggressive cancer types with their advanced lineup of lymph node-targeted immunotherapies. Their cutting-edge AMP technology is designed to deliver therapeutic agents directly to lymph nodes, enhancing the immune system's natural ability to fight cancer. This approach is intended to educate, activate, and amplify the effectiveness of cancer-specific T cells, which are crucial for identifying and eliminating tumors.
About the Amphiphile Platform
The proprietary Amphiphile (AMP) platform developed by Elicio holds significant promise by targeting the delivery of investigational treatments specifically to lymph nodes. This strategy aims to bolster the immune response in both magnitude and durability, potentially leading to more favorable clinical outcomes compared to traditional therapies. Elicio's innovative technology, created at the Massachusetts Institute of Technology, shows great potential across various cancer types.
Frequently Asked Questions
What is Elicio Therapeutics known for?
Elicio Therapeutics specializes in developing groundbreaking immunotherapies aimed at aggressive cancers, particularly through their unique amphiphile vaccines.
When will these upcoming presentations take place?
The presentations are scheduled for September 15, September 25, and October 1 in 2024.
Who are the presenters at these events?
Dr. Eileen O’Reilly, Dr. Pete DeMuth, and Dr. Christopher Haqq will be the speakers at these respective events.
What technology does Elicio use in its research?
Elicio utilizes the Amphiphile platform, which enables targeted delivery of cancer vaccines to lymph nodes, enhancing immune response effectiveness.
How does patient data contribute to Elicio’s research?
Patient data is crucial for Elicio as it provides insights into the effectiveness of their vaccines, evidenced by positive correlations between T cell responses and reduced tumor biomarkers.
